Table II.
Raw Expression Data from Representative IFN and Granulopoiesis Signature Genes in a Subset of SLE Patients
| Granulopoiesis signature
|
IFN signature
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLE patient no. |
SLE DAI |
Treatment | % Granulocytes |
MPO | Elastase | DEF3 | DEFA1 | F2RPA | 2′5′ OIAS | GS3686 | HepC p44 |
MX1 |
| 30 | 20 | N*
|
22.1 |
249
(3.2) |
312
(3.1) |
15704
(4.5) |
5064
(6.8) |
843
(4.1) |
2876
(3.6) |
4416
(25.2) |
5176
(14.5) |
3775
(10.0) |
| 27 | 12 | Y | 14.6 |
3539
(49.3) |
5847
(63.6) |
26594
(8.4) |
29984
(43.6) |
192
(1.0) |
1157
(1.6) |
1384
(8.6) |
1569
(4.8) |
666
(1.9) |
| 26 | 12 | N*
|
15.4 |
2203
(33.6) |
6115
(73.0) |
11414
(3.9) |
11454
(18.3) |
333
(1.9) |
1842
(2.8) |
1334
(9.0) |
744
(2.5) |
1337
(4.2) |
| 25 | 12 | N*
|
11.0 |
862
(9.8) |
2813
(25.0) |
59928
(15.4) |
30013
(35.8) |
665
(2.9) |
1615
(2.9) |
3285
(16.6) |
2074
(5.2) |
3903
(9.2) |
| 24 | 12 | N*
|
4.3 |
183
(2.6) |
419
(4.7) |
12591
(4.1) |
1539
(2.3) |
366
(2.0) |
2098
(3.0) |
2005
(12.8) |
1784
(5.6) |
2976
(8.9) |
| 23 | 11 | N*
|
13.7 |
754
(6.9) |
1297
(9.3) |
53375
(11.1) |
19953
(19.2) |
696
(2.5) |
1418
(1.3) |
1173
(4.8) |
1830
(3.7) |
1652
(3.1) |
| 22 | 10 | Y | 30.5 |
3765
(53.7) |
6911
(77.0) |
20815
(6.7) |
23042
(34.4) |
365
(2.0) |
1704
(2.4) |
2171
(13.8) |
1090
(3.4) |
1342
(4.0) |
| 17 | 8 | Y | 8.2 |
963
(9.6) |
1055
(8.2) |
32365
(7.3) |
3701
(3.9) |
449
(1.7) |
4071
(4.0) |
3266
(14.5) |
2142
(4.7) |
1127
(2.3) |
| 15 | 8 | Y | 6.5 |
168
(2.3) |
285
(3.0) |
18265
(5.6) |
3700
(5.3) |
531
(2.8) |
3463
(4.7) |
2387
(14.5) |
2741
(8.2) |
4385
(12.4) |
| 10 | 4 | Y | 2.2 |
722
(10.0) |
1552
(16.8) |
27089
(8.5) |
11268
(16.3) |
388
(2.0) |
1299
(1.8) |
703
(4.3) |
795
(2.4) |
826
(2.4) |
| 29 | 18 | N | 0.7 |
70
(1.0) |
56
(0.6) |
2414
(0.8) |
463
(0.7) |
133
(0.7) |
2822
(4.0) |
3751
(24.1) |
2391
(7.5) |
2944
(8.8) |
| 14 | 8 | Y | 1.1 |
68
(0.8) |
52
(0.5) |
10499
(2.8) |
1035
(1.3) |
265
(1.2) |
4360
(5.0) |
5211
(27.2) |
3627
(9.3) |
5214
(12.7) |
| 7 | 2 | N*
|
0.6 |
107
(1.6) |
88
(1.0) |
6026
(2.1) |
1868
(3.0) |
144
(0.8) |
1713
(2.6) |
1872
(12.8) |
1132
(3.8) |
1450
(4.6) |
| 5 | 2 | Y | 0.4 |
56
(0.7) |
82
(0.8) |
1827
(0.5) |
479
(0.6) |
462
(2.2) |
2066
(2.5) |
2601
(14.4) |
1562
(4.5) |
2676
(6.9) |
| 4 | 2 | Y | 0.7 |
77
(1.1) |
12
(0.1) |
390
(0.1) |
31
(0.05) |
204
(1.1) |
1742
(2.4) |
1298
(8.2) |
1454
(4.5) |
1021
(3.0) |
| 9 healthy donors | <0.1 |
71
± 22 |
94
± 88 |
3221
± 3004 |
716
± 947 |
186
± 90 |
712
± 116 |
158
± 49 |
322
± 71 |
338
± 67 |
||
The granulopoiesis signature is independent of treatment and is found only in patients with immature granulocytes. Raw signal values with a “per chip” normalization applied are shown in bold; Normalized values are shown in italics. N*, new untreated patient; N, untreated patient; Y, treated patient. % granulocytes: fraction of granular cells from the gated viable cells of the PBMCs isolated over Ficoll.